This activity is part of the Clinical Spotlight Series: Tracking the CV Impact of SGLT2i: Practice Essentials.
Accreditation Statement
In accordance with ACCME policy, prior to participating in this activity, you must review the information on this page.
Joint Accreditation
In support of improving patient care, the American College of Cardiology Foundation (ACCF) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Statement
Physicians
The ACCF designates this online enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
While offering the CME credits noted above, this program is not intended to provide extensive training or certification in the field.
Nurses
The ACCF designates this educational activity for a maximum of 1.50 continuing nursing education contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.
MOC Information
Successful completion of this CME/MOC activity, which includes participation in the posttest component, enables the participant to earn up to 1.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
EBAC Information
This activity "Clinical Spotlight Series" is accredited by the European Board for Accreditation in Cardiology (EBAC) for External CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME) and the European Board for Accreditation in Cardiology (EBAC) have recognized each other’s accreditation systems as substantially equivalent. Apply for credit through the post-course evaluation.
While offering credits noted above, the course is not intended to provide extensive training or certification in this field.
Target Audience
This activity is intended for CV team clinicians including physicians, nurse practitioners, physician assistants and pharmacists who manage patients with or at risk for ASCVD and/or heart failure.
Important Dates:
Date of Release: May 17, 2021
Term of Approval/Date of Credit Expiration: May 17, 2022
Learner Objectives
Upon completion of this program, you should be able to:
- Evaluate the relevant clinical trials that impact the emerging indications of SGLT2 inhibitors.
- Identify the clinical indications and key considerations for patient selection for SGLT2 inhibitors.
- Apply practical approaches for utilizing SGLT2 inhibitors in clinical practice, including initiation, dosing, dose modifications, contraindications, cautions, and adverse effects.
Acknowledgements
Educational grant support provided by: AstraZeneca and Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC
Method of Participation and Credit Certificate
Credit claiming is available until December 31, 2022. You may only complete the evaluation and claim credit once; therefore, please do not proceed until you have finished your participation in the certified content for which you wish to claim credit.
Faculty:
Alison Bailey, MD, FACC
Deepak Bhatt, MD, MPH, FACC
Javed Butler, MBBS, FACC
Michelle Kittleson, MD, FACC